Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial

201945 citationsJournal Articlebronze Open Access

Authors

Ralinepag reduced PVR compared with placebo in PAH patients on mono (41%) or dual combination (59%) background therapy.

Good health and well-being

Published in: European Respiratory Journal

Volume 54, Issue 4, pp. 1901030-1901030

Field-Weighted Citation Impact: 4.15